Evolution of Immunotherapy and Maintenance Therapy for Advanced Urothelial Carcinoma

Learn about the most clinically influential developments in leveraging immune checkpoint inhibitor–based therapy for first-line, second-line, and maintenance treatment of advanced urothelial carcinoma.
Cora N. Sternberg, MD, FACP
Format: Microsoft PowerPoint (.ppt)
File Size: 2.39 MB
Released: February 26, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Immunomedics, Inc.

Related Content

Clinical Care Options (CCO): Expert analysis from Drs. Daniel Petrylak and Toni Choueiri on key data in genitourinary cancers from ASCO GU 2022

Toni K. Choueiri, MD Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 18, 2022 Expired: April 17, 2023

Expert slides on key data from ASCO GU 2022 on prostate cancer, urothelial cancers, renal cell carcinoma, and more, from Clinical Care Options (CCO)

Released: February 28, 2022

Clinical Care Options (CCO): Joshua Sabari, MD, provides insights into the emerging targeted therapies for patients with NRG1-positive solid tumors

Joshua Sabari, MD Released: February 28, 2022

Expert commentary previewing key studies at 2022 ASCO Genitourinary Cancers Symposium annual meeting, from Clinical Care Options (CCO)

Toni K. Choueiri, MD Daniel P. Petrylak, MD Released: February 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings